Parkman Healthcare Partners LLC Reduces Position in AnaptysBio, Inc. (NASDAQ:ANAB)

Parkman Healthcare Partners LLC trimmed its position in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 46.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 138,100 shares of the biotechnology company's stock after selling 118,207 shares during the period. Parkman Healthcare Partners LLC owned 0.45% of AnaptysBio worth $4,626,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Values First Advisors Inc. bought a new stake in AnaptysBio in the third quarter worth $49,000. nVerses Capital LLC grew its position in AnaptysBio by 700.0% during the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company's stock valued at $54,000 after purchasing an additional 1,400 shares during the last quarter. Headlands Technologies LLC grew its position in AnaptysBio by 444.8% during the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company's stock valued at $89,000 after purchasing an additional 2,900 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in AnaptysBio by 81.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company's stock valued at $195,000 after purchasing an additional 2,600 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of AnaptysBio during the first quarter valued at approximately $222,000.

Insider Transactions at AnaptysBio

In related news, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the transaction, the insider now directly owns 15,398 shares of the company's stock, valued at $595,440.66. This trade represents a 8.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Dennis Mulroy sold 12,220 shares of AnaptysBio stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the transaction, the chief financial officer now directly owns 4,744 shares in the company, valued at approximately $189,333.04. The trade was a 72.03 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,440 shares of company stock worth $892,936. 33.70% of the stock is currently owned by company insiders.

AnaptysBio Stock Performance

Shares of AnaptysBio stock traded up $2.08 during trading hours on Wednesday, hitting $24.08. The company's stock had a trading volume of 475,773 shares, compared to its average volume of 358,667. AnaptysBio, Inc. has a 12-month low of $14.75 and a 12-month high of $41.31. The business has a 50 day moving average price of $27.65 and a two-hundred day moving average price of $29.72. The company has a market cap of $732.73 million, a PE ratio of -3.86 and a beta of -0.11.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. The business had revenue of $30.02 million for the quarter, compared to analysts' expectations of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. As a group, research analysts anticipate that AnaptysBio, Inc. will post -6.02 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have commented on ANAB. HC Wainwright cut their target price on AnaptysBio from $55.00 to $52.00 and set a "buy" rating on the stock in a research note on Wednesday, November 6th. Guggenheim increased their price objective on AnaptysBio from $75.00 to $90.00 and gave the company a "buy" rating in a research report on Monday, October 21st. Wedbush reaffirmed an "outperform" rating and set a $42.00 price target on shares of AnaptysBio in a report on Thursday, November 14th. Truist Financial raised their price target on shares of AnaptysBio from $20.00 to $30.00 and gave the company a "hold" rating in a report on Thursday, August 15th. Finally, JPMorgan Chase & Co. dropped their target price on shares of AnaptysBio from $75.00 to $66.00 and set an "overweight" rating on the stock in a report on Tuesday, November 12th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, AnaptysBio has an average rating of "Moderate Buy" and a consensus target price of $54.64.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.